
I think Dr. Kurzrock is making a very important point that some people are missing. I asked Claude to create an illustration of what I mean. For a given cancer, the incidence is relatively fixed, which means the clinical trial patient pool is relatively fixed. Same pool of patients buys you 24 small ORR trials or 2 big crossover OS trials. Also, a big crossover OS RCT DOES NOT guarantee to give you a BETTER drug - which is the point @Dr_R_Kurzrock is making. Over lets say 15 years, as a PUBLIC POLICY, what regulatory approval standards will give you the GREATEST IMPROVEMENT IN CANCER CARE? This is completely DIFFERENT from the question: "which trial design will give you the most ACCURATE assessment of an individual drug's efficacy?" I also understand the argument that patients will end up paying for drugs that may not work better than SOC. Sure, this may be true at any given snapshot in time, but it is UNLIKELY TO BE TRUE over 24 iterations across 15 years. Also. I don't buy the argument that you save society money, as the # of patients treated is also relatively fixed. The same $$$ will be spent on the older SOC.
You didn’t need a RCT for 94% cure rate. RCT also got us Lonsurf with a 1.5% response rate, and decades of approved drugs in multiple solid tumors with median PFS or even OS of 6 to 13 months (“breakthroughs”)























